Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lymphoma, Large B-Cell, Diffuse 2Turcot syndrome 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Muscle Invasive Bladder Cancer 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Ascites 1Advanced Solid Tumours 1Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck 1Advanced Solid Malignancies 1

Interventions

sintilimab 1danvatirsen 1catumaxomab 1aflibercept 1Zoledronic Acid 1Quality of Life 1Portasystemic Shunt, Transjugular Intrahepatic 1Octreotide 1Nutritional Status 1Interviews as Topic 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Ascites × danvatirsen × Clear all
NCT02417753 2017-05-15

AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
1 enrolled 10 charts
GastrointestinalGynecologic

Ascites, Gastrointestinal Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡